Investigational drug · Phase 2
Bosmolisib
Also called: BR101801
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Peripheral T Cell Lymphoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "Bosmolisib"
First trial start
2026
Feb 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Bosmolisib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Peripheral T Cell Lymphoma
Approved drugs for the same conditions: Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Bosmolisib" as an intervention, largest first.
- A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.Not yet recruiting
Boryung Pharmaceutical Co., LtdIndustry
NCT07180771 · 44 participants (planned) · Start Feb 2026 · Primary completion Sep 2027
Drug: BR101801 · For: Peripheral T Cell Lymphoma
Newest research
PubMed records naming it or its code names, newest first.
- Bosmolisib (BR101801), a novel PI3K-δ/γ and DNA-PK inhibitor for relapsed/refractory patients with peripheral T-cell lymphoma: a phase I study.
Kim TM, Kim SJ, Kim JS, et al. · Blood Cancer J 2026
- Dual PI3Kδ/γ inhibition enhances radiotherapy-induced antitumor immunity via macrophage-dependent cGAS-STING-type I interferon signaling.
Kim YH, Kim JS · Biochem Biophys Res Commun 2026
- BR101801 enhances the radiosensitivity of p53-deficient colorectal cancer cells by inducing G2/M arrest, apoptosis, and senescence in a p53-independent manner.
Park M, Ha J, Lee Y, et al. · Am J Cancer Res 2023
- A combination of BR101801 and venetoclax enhances antitumor effect in DLBCL cells via c-Myc/Bcl-2/Mcl-1 triple targeting.
Jeon B, Lee YJ, Shin J, et al. · Am J Cancer Res 2023
- PI3Kδ/γ inhibitor BR101801 extrinsically potentiates effector CD8+ T cell-dependent antitumor immunity and abscopal effect after local irradiation.
Yoon YN, Lee E, Kwon YJ, et al. · J Immunother Cancer 2022
- Synergistic radiosensitizing effect of BR101801, a specific DNA-dependent protein kinase inhibitor, in various human solid cancer cells and xenografts.
Lee JH, Jeon B, Park M, et al. · Am J Cancer Res 2021
Also in development for Peripheral T Cell Lymphoma
- TucidinostatChidamide, HBI-8000Phase 39 trials
Chipscreen Biosciences, Ltd. · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
- AZD4205Phase 23 trials
Dizal Pharmaceuticals · Non-small Cell Lung Cancer, Peripheral T-cell Lymphoma, Peripheral T Cell Lymphoma
- HH2853Phase 22 trials
Haihe Biopharma Co., Ltd. · Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL), FL Lymphoma, Epithelioid Sarcoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.